Early studies highlight the promise of prostate-specific membrane antigen–targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guided approaches, supported by high-quality clinical evidence, to translate feasibility into meaningful oncological benefits.
Early studies highlight the promise of prostate-specific membrane antigen–targeted fluorescence-guided surgery. Realization of the full potential of this strategy will require ongoing technical refinement and the integration of hybrid-guided approaches, supported by high-quality clinical evidence, to translate feasibility into meaningful oncological benefits.